MORRISVILLE, N.C., Could 03, 2021 (Globe NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only completely integrated biopharmaceutical remedies organization, today introduced it commenced an underwritten secondary giving by affiliate marketers of Thomas H. Lee Partners, L.P. and Introduction International Corporation (the “Selling Stockholders”) of an aggregate of 7,000,000 shares of the Company’s popular stock (the “Offering”) pursuant to the Company’s shelf registration assertion submitted with the Securities and Exchange Commission (“SEC”). The Offering Stockholders intend to grant the underwriter a 30-day choice to purchase up to 1,050,000 extra shares of popular inventory. Syneos Wellness is not promoting any shares and will not receive any proceeds from the sale of the shares by the Marketing Stockholders in the Featuring.
In addition, Syneos Well being entered into an arrangement with the Marketing Stockholders to repurchase an combination of 400,000 shares of common stock from these types of Advertising Stockholders in a personal transaction, concurrently with the closing of the Providing, at the rate at which the shares of widespread inventory are sold to the public in the Offering, fewer underwriting special discounts and commissions. The closing of the share repurchase is contingent on, and anticipated to take place at the same time with, the closing of the Supplying, subject to the fulfillment of other customary ailments. The closing of the Supplying is not contingent on the closing of the share repurchase.
B of A Securities is acting as the sole underwriter of the Providing.
The underwriter proposes to give the shares of common inventory from time to time for sale in one particular or more transactions on the Nasdaq, in the in excess of-the-counter marketplace, by negotiated transactions or normally at marketplace rates prevailing at the time of sale, at rates relevant to prevailing marketplace price ranges or at negotiated costs.1
An computerized shelf registration assertion (which include a prospectus) relating to the Supplying was filed with the SEC on November 27, 2018 and grew to become effective on filing. Just before you spend, you should read through the registration statement, prospectus and other documents Syneos Overall health has built offered with the SEC for data about Syneos Health and the Supplying. You may well get hold of these documents absolutely free of demand by viewing EDGAR on the SEC web site at www.sec.gov. Alternatively, copies of the prospectus and accompanying prospectus complement, when available, could be acquired from: B of A Securities, Inc. NC1-004-03-43 200 N. College or university St., 3rd Ground Charlotte, NC 28255-0001 attn: Prospectus Division electronic mail: [email protected]
This push launch shall not represent an offer you to offer or the solicitation of an supply to acquire, nor shall there be any sale of these securities in any condition or other jurisdiction in which these kinds of an supply, solicitation or sale would be unlawful prior to registration or qualification under the securities legal guidelines of any this kind of condition or other jurisdiction.
Other than for historical info, all of the statements, anticipations, and assumptions contained in this press release are forward-wanting statements as that term is described in the Non-public Securities Litigation Reform Act of 1995. True benefits could possibly vary materially from people specific or implicit in the forward-on the lookout statements. Critical variables that could cause true outcomes to vary materially involve, but are not constrained to: reliance on important personnel principal investigators and people standard and global financial, political, and other dangers, including currency and inventory marketplace fluctuations and the unsure financial ecosystem any failure to realize the anticipated positive aspects of the acquisitions of SHCR Holdings Company, or Synteract, and Illingworth Study Group risks connected to the COVID-19 pandemic the Company’s capacity to adequately rate its contracts and not overrun expense estimates any adverse effects from the Company’s purchaser or therapeutic region focus the Company’s skill to sustain or deliver new small business awards the Company’s capability to boost its current market share, grow its organization, and execute its development tactics the Company’s backlog not staying indicative of upcoming revenues and its capacity to know the predicted long run profits reflected in its backlog fluctuations in the Company’s running results and helpful profits tax fee pitfalls linked to the Company’s information and facts programs and cybersecurity alterations and expenditures of compliance with regulations similar to facts privateness threats linked to the United Kingdom’s withdrawal from the European Union dangers linked to the Company’s transfer pricing procedures failure to accomplish companies in accordance with contractual specifications, regulatory needs and ethical criteria dangers relating to litigation and federal government investigations risks associated with the Company’s early phase clinical services insurance coverage hazard threats of legal responsibility ensuing from harm to patients good results of investments in the Company’s customers’ company or drugs overseas forex exchange level fluctuations dangers involved with acquired organizations, which include the capacity to combine acquired functions, merchandise, and technologies in our business threats related to the Company’s cash flow tax price and tax reform challenges relating to the Company’s intellectual residence risks affiliated with the Company’s acquisition tactic failure to notice the total value of goodwill and intangible assets restructuring danger potential violations of anti-corruption and anti-bribery regulations hazards associated to the Company’s dependence on 3rd get-togethers downgrades of the Company’s credit rating ratings competition in the biopharmaceutical companies field alterations in outsourcing trends regulatory risks trends in the Company’s customers’ organizations the Company’s means to hold pace with swift technological change challenges relevant to the Company’s indebtedness fluctuations in the Company’s economic final results and stock selling price and other risk components set forth in the Company’s Annual Report on Variety 10-K for the fiscal calendar year ended December 31, 2020 and other SEC filings, copies of which are available absolutely free of demand on the SEC internet site at www.sec.gov. The Corporation assumes no obligation and does not intend to update these ahead-searching statements, except as demanded by regulation.
About Syneos Well being
Syneos Wellbeing® (Nasdaq:SYNH) is the only thoroughly integrated biopharmaceutical alternatives organization. The Firm, together with a Deal Research Group (CRO) and Contract Commercial Business (CCO), is reason-constructed to accelerate buyer efficiency to tackle present day industry realities. We deliver alongside one another roughly 25,000 scientific and business minds with the potential to guidance consumers in more than 110 nations around the world. With each other we share insights, use the most recent technologies and utilize innovative business procedures to pace our customers’ delivery of significant therapies to people.
1 Include things like in a variable price reoffer.